Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Septicaemia - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 34 | Code: MRS - 18565


Global Markets Directs, Septicaemia Pipeline Review, H2 2014, provides an overview of the Septicaemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septicaemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septicaemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Septicaemia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Septicaemia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Septicaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Septicaemia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Septicaemia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Septicaemia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Septicaemia Overview 6
Therapeutics Development 7
Pipeline Products for Septicaemia - Overview 7
Pipeline Products for Septicaemia - Comparative Analysis 8
Septicaemia - Therapeutics under Development by Companies 9
Septicaemia - Therapeutics under Investigation by Universities/Institutes 10
Septicaemia - Pipeline Products Glance 11
Early Stage Products 11
Septicaemia - Products under Development by Companies 12
Septicaemia - Products under Investigation by Universities/Institutes 13
Septicaemia - Companies Involved in Therapeutics Development 14
Cubist Pharmaceuticals, Inc. 14
Diomune S.L 15
Humabs BioMed SA 16
Sinovac Biotech Ltd. 17
Septicaemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Molecule Type 23
Drug Profiles 25
Monoclonal Antibody for Staphylococcus Aureus Infections - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Oncocin Analogues for Septicaemia - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
pneumococcal polysaccharide (23-valent) vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules for Human Septicaemia - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Septicaemia - Recent Pipeline Updates 31
Septicaemia - Discontinued Products 32

Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables

Number of Products under Development for Septicaemia, H2 2014 7
Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Septicaemia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 14
Septicaemia - Pipeline by Diomune S.L, H2 2014 15
Septicaemia - Pipeline by Humabs BioMed SA, H2 2014 16
Septicaemia - Pipeline by Sinovac Biotech Ltd., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Septicaemia Therapeutics - Recent Pipeline Updates, H2 2014 31
Septicaemia - Discontinued Products, H2 2014 32

List of Figures

Number of Products under Development for Septicaemia, H2 2014 7
Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Targets, H2 2014 19
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Top 10 Molecule Types, H2 2014 23
Number of Products by Stage and Top 10 Molecule Types, H2 2014 23

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing